In lat­est turn to au­toim­mune ther­a­pies, Cul­li­nan nabs $280M to join lu­pus space

At Cul­li­nan, im­munol­o­gy is quite lit­er­al­ly the new on­col­o­gy.

The biotech an­nounced Tues­day that it’s ex­pand­ing its pipeline from can­cer to in­clude im­munol­o­gy and chang­ing its name from Cul­li­nan On­col­o­gy to Cul­li­nan Ther­a­peu­tics. By do­ing so, the com­pa­ny is join­ing the au­toim­mune craze, be­com­ing the lat­est biotech to ei­ther add or piv­ot to­ward a pro­gram test­ing ground­break­ing can­cer treat­ments in lu­pus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER